84 related articles for article (PubMed ID: 7615956)
1. Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension.
Sánchez-Margalet V; Valle M; Lobón JA; Maldonado A; Escobar-Jimenez F; Oliván J; Pérez-Cano R; Goberna R
J Hypertens; 1995 Feb; 13(2):251-8. PubMed ID: 7615956
[TBL] [Abstract][Full Text] [Related]
2. Normal pancreastatin-like and increased post-glucose insulin levels in young offspring of insulin-resistant non-obese essential hypertensive patients.
Sánchez-Margalet V; Ramos E; Mateo J; Oliván J; Pérez-Cano R; Goberna R
J Endocrinol; 1997 May; 153(2):313-8. PubMed ID: 9166122
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels.
Sánchez-Margalet V; Lobón JA; González A; Fernández-Soto ML; Escobar-Jiménez F; Goberna R
Diabetes Care; 1998 Nov; 21(11):1951-4. PubMed ID: 9802749
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin level versus blood pressure: a cross-sectional, case-controlled study in non-obese, middle-aged Japanese subjects with normal glucose tolerance.
Baba T; Kodama T; Tomiyama T; Sohn DR; Ishizaki T
Diabet Med; 1994; 11(1):42-9. PubMed ID: 8181251
[TBL] [Abstract][Full Text] [Related]
5. Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice.
Ahrén B; Lindskog S; Tatemoto K; Efendić S
Diabetes; 1988 Mar; 37(3):281-5. PubMed ID: 3286328
[TBL] [Abstract][Full Text] [Related]
6. Suppression of non-esterified fatty acid concentrations by insulin in patients with hypertension.
Sheu WH; Jeng CY; Shieh SM; Fuh MM
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Dec; 56(6):367-72. PubMed ID: 8851476
[TBL] [Abstract][Full Text] [Related]
7. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Funakoshi A; Tateishi K; Shinozaki H; Matsumoto M; Wakasugi H
Regul Pept; 1990 Sep; 30(2):159-64. PubMed ID: 2274680
[TBL] [Abstract][Full Text] [Related]
8. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism.
O'Connor DT; Cadman PE; Smiley C; Salem RM; Rao F; Smith J; Funk SD; Mahata SK; Mahata M; Wen G; Taupenot L; Gonzalez-Yanes C; Harper KL; Henry RR; Sanchez-Margalet V
J Clin Endocrinol Metab; 2005 Sep; 90(9):5414-25. PubMed ID: 15956083
[TBL] [Abstract][Full Text] [Related]
9. Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension.
Sánchez-Margalet V; Valle M; Lobón JA; Escobar-Jiménez F; Pérez-Cano R; Goberna R
Neuropeptides; 1995 Aug; 29(2):97-101. PubMed ID: 7477767
[TBL] [Abstract][Full Text] [Related]
10. Pancreastatin distribution and plasma levels in the pig.
Bretherton-Watt D; Ghatei MA; Bishop AE; Facer P; Fahey M; Hedges M; Williams G; Valentino KL; Tatemoto K; Roth K
Peptides; 1988; 9(5):1005-14. PubMed ID: 3244555
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.
Syversen U; Mignon M; Bonfils S; Kristensen A; Waldum HL
Acta Oncol; 1993; 32(2):161-5. PubMed ID: 8323758
[TBL] [Abstract][Full Text] [Related]
12. Galanin and pancreastatin inhibit stimulated insulin secretion in the mouse: comparison of effects.
Lindskog S; Ahrén B
Horm Res; 1988; 29(5-6):237-40. PubMed ID: 2464535
[TBL] [Abstract][Full Text] [Related]
13. Glycogenolytic effect of pancreastatin in the rat.
Sanchez V; Calvo JR; Goberna R
Biosci Rep; 1990 Feb; 10(1):87-91. PubMed ID: 2187544
[TBL] [Abstract][Full Text] [Related]
14. Life style changes improve insulin resistance in hyperinsulinaemic subjects: a one-year intervention study of hypertensives and normotensives in Dalby.
Nilsson PM; Lindholm LH; Scherstén BF
J Hypertens; 1992 Sep; 10(9):1071-8. PubMed ID: 1328367
[TBL] [Abstract][Full Text] [Related]
15. Autocrine regulation of parathyroid secretion: inhibition of secretion by chromogranin-A (secretory protein-I) and potentiation of secretion by chromogranin-A and pancreastatin antibodies.
Fasciotto BH; Gorr SU; Bourdeau AM; Cohn DV
Endocrinology; 1990 Sep; 127(3):1329-35. PubMed ID: 2387256
[TBL] [Abstract][Full Text] [Related]
16. [Pancreastatin secretion stimulation in healthy volunteers].
Zagórowicz E; Bak M; Siemińska J; Muszyński J
Pol Arch Med Wewn; 2002 Dec; 108(6):1185-91. PubMed ID: 12687931
[TBL] [Abstract][Full Text] [Related]
17. Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man.
Siegel EG; Gallwitz B; Fölsch UR; Schmidt WE
Exp Clin Endocrinol Diabetes; 1998; 106(3):178-82. PubMed ID: 9710357
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Alvarez J
Regul Pept; 2010 Apr; 161(1-3):8-14. PubMed ID: 20184923
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor alpha -238 and -308 polymorphisms do not associate with insulin resistance in hypertensive subjects.
Sheu WH; Lee WJ; Lin LY; Chang RL; Chen YT
Metabolism; 2001 Dec; 50(12):1447-51. PubMed ID: 11735091
[TBL] [Abstract][Full Text] [Related]
20. Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas.
Prévost G; Eas F; Duparc C; Cauliez B; Laquérrière A; Fréger P; Lefebvre H; Kuhn JM
Horm Metab Res; 2012 Oct; 44(11):861-5. PubMed ID: 22864906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
